Celcuity Inc. (NASDAQ: CELC) Securities Fraud Investigation

Celcuity Announces Unexpected Delayed Drug Launch
On July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) and “anticipates commercial launch in late Q3 2026”, representing a delayed launch timeline relative to analyst expectations. Commenting on the announcement, a Stifel analyst noted that “late 3Q26 launch guidance seems somewhat extended.” A Leerink analyst agreed, noting that while the “approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.”

Celcuity’s Stock Drops Over 17%
Following the news of Celcuity Inc.’s delayed drug launch, the company’s stock price fell over 17%.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at [email protected].  

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: 
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.